# Mounjaro Canada: New Heart Approval, Price, Coverage (2026)

Source: https://www.dietglp.com/blog/mounjaro-canada/
Published: 2026-11-18
Keywords: mounjaro canada, mounjaro canada price, mounjaro canada cost, mounjaro canada coverage, mounjaro canada indications, mounjaro canada savings card, mounjaro canada for weight loss, mounjaro canada availability, mounjaro canada product monograph, mounjaro canada side effects, mounjaro canada diabetes, mounjaro canada generic, mounjaro canada vs ozempic, mounjaro cost canada

**TL;DR:** Mounjaro (tirzepatide) in Canada now has two uses: blood sugar control in type 2 diabetes, and, since Health Canada's approval announced on November 18, 2026, lowering the risk of heart attack, stroke and heart death in adults with type 2 diabetes and established heart disease. For weight loss without diabetes, the same drug is sold in Canada as Zepbound. Lilly's submitted list price is $300 to $540 per four-dose KwikPen, before pharmacy fees, and public plans cover it only for diabetes, if at all. While you are on it, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps you keep muscle with one protein target and one 20-minute workout a day.

Is Mounjaro available in Canada, what is it approved for, and what does it cost? Here is the short answer. Mounjaro (tirzepatide) is a Health Canada approved type 2 diabetes medicine. On November 18, 2026, Eli Lilly Canada announced that Health Canada added a heart indication. Mounjaro can now be used to lower the risk of heart attack, stroke and heart death in adults with type 2 diabetes who already have heart disease. It is not approved for weight loss alone in Canada. That role belongs to Zepbound, the same drug under a different name.

This guide covers the new approval, every Canadian use, the price, coverage and the savings card.

## What Health Canada approved on November 18, 2026

Health Canada issued a Notice of Compliance for the new use. In plain words, the label now says Mounjaro lowers the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease. MACE means three things: death from heart or blood vessel disease, a heart attack, or a stroke.

The proof came from SURPASS-CVOT. It was the first heart outcomes trial to test two incretin drugs against each other instead of against a placebo.

| SURPASS-CVOT detail | What it showed |
|---|---|
| People | More than 13,000 adults with type 2 diabetes and heart disease |
| Where | 30 countries, including Canada |
| Compared with | Trulicity (dulaglutide), a drug already shown to protect the heart |
| Length | More than four and a half years from start to finish |
| Heart attack, stroke or heart death | 8% lower rate on Mounjaro (hazard ratio 0.92) |
| Verdict | Not worse than Trulicity; "better than" was not proven |
| Side effects | Mostly stomach problems, mild to moderate, mainly while the dose was going up |

The trend favored Mounjaro, but the range of possible results (95.3% CI 0.83 to 1.01) still includes no difference. So the fair summary is "at least as good as Trulicity." We broke down the full trial, including the US version of this approval from August 2026, in our [Mounjaro heart benefits guide](/blog/mounjaro-heart-benefits/).

## Mounjaro Canada indications: the full list

Canada and the US now both have a heart indication, but the wording is not the same.

| Use | Canada | United States |
|---|---|---|
| Blood sugar control in type 2 diabetes | Yes (adults, and children 10 and older per Lilly Canada) | Yes (adults and children 10 and older) |
| Lower heart risk in type 2 diabetes | Yes, adults with established heart disease (Nov 2026) | Yes, adults at high heart risk (Aug 2026) |
| Weight loss without diabetes | No, use Zepbound | No, use Zepbound |
| Sleep apnea with obesity | No, Zepbound has it (June 2026) | No, Zepbound has it |

The Canadian heart wording is narrower. It names people who already have heart or blood vessel disease. Ask your doctor whether you fit.

## Is Mounjaro approved for weight loss in Canada?

No. Doctors can still prescribe it off-label, but private plans often decline that. The weight loss brand is Zepbound. Health Canada authorized it on May 13, 2025 for chronic weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, type 2 diabetes or sleep apnea. Our [Zepbound vs Mounjaro guide](/blog/zepbound-vs-mounjaro/) explains why one drug carries two names.

## Mounjaro Canada price and cost

Canada's Drug Agency (CDA-AMC) published the price Lilly submitted for each multi-dose KwikPen. One pen holds four weekly doses, so it is about a four-week supply.

| Dose | Submitted list price per KwikPen (4 doses) |
|---|---|
| 2.5 mg or 5 mg | $300 |
| 7.5 mg or 10 mg | $420 |
| 12.5 mg or 15 mg | $540 |

These match the Canadian list prices that news reports said took effect on December 29, 2025. They are not what you pay at the counter. Pharmacies add a markup and a dispensing fee, and these differ by province and store, so call two or three pharmacies and compare. The dose steps themselves are set by your prescriber; see our [Mounjaro dosage chart](/blog/mounjaro-dosage-chart/) for how the label lays them out.

Prices are far lower in Japan, where tirzepatide is on the national insurance price list; see our guide to [Mounjaro Japan prices and the new Korean travel rule](/blog/mounjaro-japan/).

## Is Mounjaro covered in Canada?

- **Public drug plans.** CDA-AMC recommended, by a 12 to 0 vote, that public plans cover Mounjaro for adults with type 2 diabetes, with conditions. The conditions include using the same rules plans already use for other GLP-1 drugs and a price cut so the 5 mg dose costs no more than semaglutide 1 mg. Each province and territory then decides, often with special authorization.
- **Private insurance.** Plans like Canada Life, Sun Life and Manulife set their own rules. Many need a prior authorization form from your doctor.
- **Weight loss alone.** We found no public plan that covers tirzepatide for weight loss without diabetes.

The new heart indication may help on a coverage form if you have both diabetes and heart disease. It does not force any plan to pay.

## The Mounjaro savings card in Canada

Lilly Canada runs the my mounjaro Savings & Support Program. Its page lists three things: a savings card "regardless of insurance coverage," help with private insurance forms, and free digital resources. The card is for the KwikPen only, for Canadian residents with a prescription, and exclusions may apply. Lilly does not post a dollar amount on that page, so ask the program or your pharmacist what it covers. The US $25 card is a separate program and does not work in Canada; our [Mounjaro coupon card guide](/blog/mounjaro-coupon-card/) covers the US terms.

## Mounjaro vs Ozempic in Canada

Both are weekly diabetes shots with heart indications. Ozempic (semaglutide) earned its heart claim against placebo. Mounjaro earned its claim against Trulicity. No heart trial has compared Mounjaro and Ozempic head to head. Generic semaglutide is now arriving in Canada, which may make Ozempic's ingredient cheaper; our [generic semaglutide guide](/blog/generic-semaglutide/) tracks it. There is no generic tirzepatide. If you would rather take a pill, Health Canada also approved Lilly's daily GLP-1 tablet in November 2026; our [Foundayo Canada guide](/blog/foundayo-canada/) covers who qualifies and when it arrives. For a side-by-side of every brand, see our [GLP-1 medication comparison](/blog/glp1-medication-comparison/).

## Mounjaro side effects and safety

The most common side effects are nausea, diarrhea, vomiting, constipation and less appetite, mostly while the dose goes up. The Canadian product monograph, linked on lilly.ca, lists the full warnings. Get medical help for severe stomach pain that does not go away, signs of an allergic reaction, or a lump or swelling in your neck. If you are pregnant, planning a pregnancy or have an eating disorder history, talk to your doctor before starting.

## Protect your muscle while you take it

Large weight loss on tirzepatide includes some lean tissue. In the T-REx study, people on tirzepatide who lifted weights three times a week lost about 25% less lean tissue, and their strength went up instead of down. Our [Ozempic muscle loss guide](/blog/ozempic-muscle-loss/) walks through it. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) turns that into one protein target, one 20-minute workout and one Shape Score each day, so you can see whether you are losing fat, not muscle.

## Questions to ask your doctor or pharmacist

- Do I count as having "established cardiovascular disease" under the new Canadian label?
- Does my province cover Mounjaro for my diabetes, and what form is needed?
- Am I eligible for the my mounjaro savings card with my plan?
- If I need weight loss treatment and do not have diabetes, is Zepbound the right brand for me?

## Bottom line

Mounjaro in Canada is a diabetes drug that now also has an approved heart benefit for people with diabetes and heart disease. For weight loss alone, Canadians use Zepbound. Lilly's list price runs $300 to $540 per four-week pen before pharmacy fees, and coverage depends on your province or private plan. Whichever brand you take, protein and strength work protect the muscle you want to keep, and [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) keeps both in one simple daily plan.

## Sources

- [Health Canada approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, Eli Lilly Canada via Cision, November 18, 2026](https://www.newswire.ca/news-releases/health-canada-approves-lilly-s-mounjaro-r-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-898711954.html)
- [Tirzepatide (Mounjaro) reimbursement recommendation, Canada's Drug Agency (CDA-AMC), Canadian Journal of Health Technologies](https://canjhealthtechnol.ca/index.php/cjht/article/view/SR0886/3644)
- [Mounjaro availability in Canada, Lilly Canada](https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen/learn-about-availability)
- [Mounjaro patient support and savings, Lilly Canada](https://www.lilly.com/en-ca/medicines/medicine-faqs/mounjaro-kwikpen/patient-support-savings)
- [Zepbound KwikPen now approved and available in Canada, Eli Lilly Canada, July 9, 2025](https://www.biospace.com/press-releases/zepbound-kwikpen-tirzepatide-injection-the-first-and-only-dual-receptor-agonist-for-the-treatment-of-obesity-now-approved-and-available-in-canada)
- [Health Canada approves Zepbound for obstructive sleep apnea in adults with obesity, Eli Lilly Canada, June 2026](https://www.biospace.com/press-releases/health-canada-approves-zepbound-as-the-first-ever-obstructive-sleep-apnea-medication-in-canada-for-adults-living-with-obesity)
- [Eli Lilly cuts Canadian obesity drug prices, Benefits and Pensions Monitor, December 19, 2025](https://www.benefitsandpensionsmonitor.com/benefits/pharma/eli-lilly-cuts-canadian-obesity-drug-prices/392905)
- [Summary Basis of Decision for Mounjaro, Health Canada](https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00629)
- [Resistance training key to maintaining muscle function during GLP-1 weight loss, University of Western Australia, November 2026](https://www.uwa.edu.au/news/article/2026/november/resistance-training-key-to-maintaining-muscle-function-during-glp1-weight-loss)


## Frequently asked questions

**Q: Is Mounjaro approved in Canada?**

A: Yes. Health Canada first approved Mounjaro in November 2022 for blood sugar control in type 2 diabetes. On November 18, 2026, Lilly Canada announced a second approval: lowering the risk of major heart events in adults with type 2 diabetes and established cardiovascular disease.

**Q: Is Mounjaro approved for weight loss in Canada?**

A: No. Mounjaro is a type 2 diabetes medicine in Canada. The same drug, tirzepatide, is approved for chronic weight management under the brand Zepbound, authorized by Health Canada on May 13, 2025 for adults with a BMI of 30 or more, or 27 or more with a weight-related health problem.

**Q: How much does Mounjaro cost in Canada?**

A: Lilly's submitted list price, as reported by Canada's Drug Agency, is $300 per KwikPen for 2.5 mg or 5 mg, $420 for 7.5 mg or 10 mg, and $540 for 12.5 mg or 15 mg. One KwikPen holds four weekly doses. Your pharmacy adds its markup and dispensing fee, so the price you pay is higher and varies by store.

**Q: Is Mounjaro covered in Canada?**

A: It depends on your plan. Canada's Drug Agency recommended in 2026 that public plans cover Mounjaro for type 2 diabetes, but only with conditions, including a lower price. Each province decides on its own. Private plans set their own rules, and many require prior authorization. We found no public plan that covers it for weight loss alone.

**Q: Is there a Mounjaro savings card in Canada?**

A: Yes. Lilly Canada runs the my mounjaro Savings & Support Program. Its page says the savings card is available regardless of insurance coverage, for the KwikPen only, to Canadian residents with a prescription. Exclusions may apply, and the US $25 card does not work in Canada.

**Q: Is there a generic Mounjaro in Canada?**

A: No generic tirzepatide is sold in Canada. The generic drugs in Canadian news are generic semaglutide, the ingredient in Ozempic, which is a different medicine. Be wary of any site selling "generic Mounjaro."

**Q: Does the new heart approval cover Zepbound?**

A: No. The November 2026 heart indication is on the Mounjaro label for adults with type 2 diabetes and established heart disease. Zepbound's own heart trial in people without diabetes, SURMOUNT-MMO, is still running.

